Stockscreener 앱 받기
10.54
2.63%
0.265
Eikon Therapeutics Inc 주식(EIKN)의 최신 뉴스
EIKN SEC FilingsEikon Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
[SCHEDULE 13G] Eikon Therapeutics, Inc. Passive Investment Disclosure (>5%) - Stock Titan
Domino's Posts Downbeat Q1 Results, Joins Real Brokerage And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Sahm
Merck reportedly eyeing $30M stake in Eikon Therapeutics’ IPO - MSN
Merck veteran-led Eikon seeks $908M valuation in US IPO - MSN
Should I be cautious with Eikon Therapeutics (EIKN) stock today (Market Focus) 2026-04-20Most Discussed Stocks - Xã Châu Thành
IPO Tracker 2026: Seaport, Hemab set sail for Nasdaq - BioSpace
ETFs Investing in Eikon Therapeutics, Inc. Stocks - TradingView
EIKN: Eikon Therapeutics, Inc.Comparison to Industry - Zacks Investment Research
EIKN : Eikon Therapeutics, Inc. Key Company Metrics & Non-finance Metrics - Zacks Investment Research
Eikon Therapeutics, Inc. News — NASDAQ:EIKN - TradingView
EIKN Forecast — Price Target — Prediction for 2027 - TradingView
Diluted shares outstanding of Eikon Therapeutics, Inc. – BX:EIKN - TradingView — Track All Markets
Number of employees of Eikon Therapeutics, Inc. – NASDAQ:EIKN - TradingView
Eikon Therapeutics, Inc. Statistics – BX:EIKN - TradingView — Track All Markets
EIKN Price Today: Eikon Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC
IPO market strengthens in Q1 2026 as biopharma financings reach $22.82B - BioWorld News
Should I buy Eikon Therapeutics, Inc. (EIKN) - Zacks Investment Research
EIKN Analyst Rating Reiterated at Underperform by Wedbush | EIKN Stock News - GuruFocus
Eikon Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Mizuho reiterates Eikon Therapeutics stock rating on pipeline update By Investing.com - Investing.com Canada
Mizuho reiterates Eikon Therapeutics stock rating on pipeline update - Investing.com
IPO Tracker 2026: Biotech Mega-Rounder Kailera Seeks IPO - BioSpace
Eikon Therapeutics Reports 2025 Financial Results, Upsized IPO, and Key Clinical Pipeline Progress - Minichart
Eikon Therapeutics Reports Q4 and Full Year 2025 Results, Provides Clinical Updates - National Today
Eikon Gains on Results - Baystreet.ca
Eikon Therapeutics Announces Fourth Quarter And Full Year 2025 Financial Results And Provides Clinical And Corporate Updates - TradingView
Eikon Therapeutics: Advancing Biopharmaceutical Innovation with Proprietary Technology Platform and Clinical-Stage Oncology Pipeline - minichart.com.sg
Eikon Therapeutics Announces Fourth Quarter and Full Year - GlobeNewswire
After a $381M IPO, Eikon fully enrolls a stage 4 lung cancer study - Stock Titan
Form 10-K Eikon Therapeutics, Inc. For: Dec 31 - StreetInsider
Eikon Therapeutics (NASDAQ: EIKN) posts 2025 loss but extends cash runway - Stock Titan
Eikon Therapeutics, Inc.(NasdaqGS: EIKN) added to S&P TMI Index - MarketScreener
Eikon Therapeutics (EIKN) Stock Analysis Report | Financials & Insights - Benzinga Japan
Eikon Therapeutics (EIKN) grants 25,873-share stock option award to director - Stock Titan
Eikon Therapeutics (EIKN) grants director Kenneth Frazier 25,873 options - Stock Titan
Large stock option grant to Eikon Therapeutics (EIKN) director and officer - Stock Titan
Eikon Therapeutics Shares Jump 6% as Brokerages Initiate Coverage By Investing.com - Investing.com Canada
Eikon Therapeutics Shares Jump 6% as Brokerages Initiate Coverage - Investing.com UK
BofA initiates Eikon Therapeutics stock with buy rating on platform potential - Investing.com Australia
BofA Securities Initiates Eikon Therapeutics at Buy With $34 Price Target - marketscreener.com
Cantor Fitzgerald Initiates Eikon Therapeutics at Overweight - marketscreener.com
This NextTrip Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Mizuho Initiates Eikon Therapeutics at Outperform With $26 Price Target - marketscreener.com
BofA initiates Eikon Therapeutics stock with buy rating on platform potential By Investing.com - Investing.com South Africa
Morgan Stanley Initiates Eikon Therapeutics at Overweight With $32 Price Target - marketscreener.com
Mizuho initiates Eikon Therapeutics stock coverage with outperform - Investing.com Nigeria
JPMorgan initiates Eikon Therapeutics stock at Overweight By Investing.com - Investing.com Nigeria
Morgan Stanley initiates Eikon Therapeutics stock coverage at overweight By Investing.com - Investing.com South Africa
Morgan Stanley initiates Eikon Therapeutics stock coverage at overweight - Investing.com India
0.78%
3.01%
자본화:
|
볼륨(24시간):